MMJ Recs

DECEMBER 28, 2023

Strains with a balanced THC and CBD ratio are often recommended for their synergistic effects in pain relief without the intense psychoactive experience. CBD, a non-psychoactive cannabinoid, has gained attention for its anti-anxiety effects. Medical cannabis, with its anxiolytic properties, offers a potential solution.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

Cannabis Law Report

NOVEMBER 25, 2021

CBD is all the rage, and has been for quite some time. Most cannabis by-products are legal these days, and the CBD industry has been booming. Here are a few reasons why CBD products are more popular than ever this year. Epilepsy Treatment. However, hope in the form of CBD seems to be on the way.

CBD 52

CBD Clinical Trials Epilepsy Chronic Pain 52

MedicalJane

JUNE 29, 2018

The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.”. On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). Prior to this week, the U.S.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

SEPTEMBER 22, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBD’s superior potency over CBD by factor of 8,000 times. Watch how Supera-CBD works. “We Chief Scientific Officer of MyMD. “We

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

CannaMD

AUGUST 8, 2020

In honor of National CBD Day, CannaMD wants to clear up some cannabinoid confusion once and for all. So sit back, relax – and if you can’t relax, grab some CBD! What is CBD? Let’s clear up one of the biggest sources of confusion right off the bat: CBD is a cannabis compound called cannabidiol.

CBD 99

CBD DEA Research and Development Hemp 99

The Joint Blog

JANUARY 31, 2021

According to a new study published in the Journal of Medical Case Reports , the daily use of high-CBD (cannabidiol) marijuana extracts is associated with improvements in the behavioral symptoms related to autism spectrum disorder (ASD). The individual was given very low-doses of marijuana extracts, no larger than 0.2 ml twice daily.

Epilepsy 62

Epilepsy Extraction Research and Development Clinical Trials 62

Cannabis Law Report

DECEMBER 1, 2021

MyMD to highlight its development pipeline for two novel therapeutics: immune regulator MYMD-1 and synthetic cannabidiol derivative Supera-CBD. During the conferences, MyMD executives will discuss the multiple indications being pursued and market opportunities for novel drug candidates MYMD-1 and Supera-CBD. About Supera-CBD.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Veriheal

APRIL 11, 2022

I look forward to a time when they are not considered alternative therapies or home remedies but actually first-line therapies,” said the CEO of Zelira, Oludare Odumosu. “I look forward to a time when they are not considered alternative therapies or home remedies but actually first-line therapies,” said the CEO of Zelira, Oludare Odumosu. “We

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Epidiolex is a CBD-infused oral-based medication designed to help patients as young as two-years-old treat epilepsy disorders.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

The Joint Blog

APRIL 22, 2022

Cannabidiol, also popularly known as CBD, is a chemical compound derived from cannabis Sativa plants. However, before consuming CBD in any form, you must seek your doctor’s advice and buy the best CBD oil on the market. Many companies offer CBD oil in multiple forms for general use. Forms of CBD. Treats Epilepsy.

Oil 26

Oil CBD Topical Clinical Trials 26

The Joint Blog

JANUARY 12, 2020

The market for CBD pet products has exploded in recent years, with numerous success stories. However, researchers warn that not only are not all CBD pet products made equally, but some contain no CBD at all. Because the federal government has yet to establish standards for CBD, these companies can get away with it.

Pets 36

Pets CBD Clinical Trials Research and Development 36

Cannabis Law Report

NOVEMBER 16, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “For

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

AUGUST 21, 2019

The watchdog refused to allow its national health service to prescribe medical cannabis for children with severe epilepsy because there is “not enough evidence it works”, a decision which angered campaigners and parents who said their children will suffer as a result. The final guideline is expected to be published in November 2019.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

JANUARY 5, 2022

This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., MyMD also holds three patents for its synthetic cannabidiol (CBD) derivative Supera-CBD. Unlike other anti-TNF-?

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

OCTOBER 26, 2021

MyMD plans to advance MYMD-1 in the clinic with two simultaneous Phase 2 trials beginning in the current quarter, one for delaying aging and prolonging healthy lifespan, and the second for COVID-19-associated depression and cytokine elevation. Unlike other therapies, MYMD-1 has been shown to selectively block TNF-?

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 23, 2021

MyMD also holds two patents for its synthetic cannabidiol (CBD) derivative Supera-CBD. MYMD-1 has shown effectiveness in pre-clinical studies in regulating the immune system by performing as a selective inhibitor of tumor necrosis factor-alpha (TNF-?), Unlike other therapies, MYMD-1 has been shown to selectively block TNF-?

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Epidiolex is a CBD-infused oral-based medication designed to help patients as young as two-years-old treat epilepsy disorders.

Research and Development 40

Research and Development Epilepsy Clinical Trials Treatment 40

The Joint Blog

FEBRUARY 24, 2021

Numerous trials have been run using medical marijuana and CBD tinctures to treat or reduce the symptoms of Parkinson’s Disease. This is not the first medicinal trial of its kind. Cannabis and CBD oils have often been used to reduce the effects of epilepsy and several other neurological issues, so why not Parkinson’s?

Treatment 55

Treatment Clinical Trials Collective Patients 55

Greencamp

AUGUST 16, 2018

The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. Marijuana and Epilepsy: Here’s How Cannabis Stops Seizures (12 Studies). Cannabidiol (CBD) and ALS. High in THC.

Strains 94

Strains Cannabinoids Research and Development Indica 94

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. tetrahydrocannabinol (THC).

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

Cannabis Law Report

SEPTEMBER 20, 2021

(“Nanomerics”) to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children. VRP324 uses a preassembled device and cartridge to propel the CBD powder formulation into the nose to the brain via the olfactory nerve/bulb.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. tetrahydrocannabinol (THC).

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Green Relief

MAY 13, 2018

The benefits of CBD-rich cannabis concentrates for chronic traumatic encephalopathy (CTE) are well-known among football players and other pro athletes. government-held patent pertaining to “cannabinoids as antioxidants and neuroprotectants,” CBD and THC can limit “neurological damage following ischemic insults, such as stroke or trauma.”.

THC 64

THC CBD Cannabinoids Research and Development 64

Cannabis Law Report

DECEMBER 21, 2019

ASD is a worldwide problem that needs to be kept in check, and although currently there is no cure to the problem so many breakthroughs have been recorded via a couple of therapy procedures amongst which is the use of CBD. A closer look at CBD And Autism. Studies conducted to validate CBD’s use for autism.

Research and Development 59

Research and Development CBD Conditions Therapy 59

Green Relief

MAY 12, 2018

The benefits of CBD-rich cannabis concentrates for chronic traumatic encephalopathy (CTE) are well-known among football players and other pro athletes. government-held patent pertaining to “cannabinoids as antioxidants and neuroprotectants,” CBD and THC can limit “neurological damage following ischemic insults, such as stroke or trauma.”.

Research and Development 40

Research and Development Cannabinoids Therapy CBD 40

Cannabis Law Report

AUGUST 12, 2019

Cannabidiol (CBD), a compound produced by the cannabis plant, is quickly growing in popularity and headed toward mainstream acceptance. CBD oil is finding its way into a variety of products, from tinctures and drops to CBD-infused edibles and CBD balms, as well as a wide range of cosmetics. A Short History of CBD Oil.

CBD 40

CBD Terpenes Oil Tincture 40

Cannabis Law Report

NOVEMBER 24, 2021

Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. Refractory paediatric epilepsy. The latter remains a dangerous drug and is considered higher risk for treatment than CBD (TGA 2019 ).

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Puff Puff Post

DECEMBER 28, 2018

One recent observational study has shown an astonishing success rate of 80% in reducing negative behavioral patterns in test subjects by using CBD oil. We go deep into what this might mean for the future of therapy for Autism Spectrum Disorders (ASD), and how we might see the use of CBD oil for autism.

Treatment 76

Treatment Oil CBD Therapy 76

Cannabis Law Report

DECEMBER 30, 2019

State lawmakers passed Assembly Bill 420 , which authorizes the University of California’s Center for Medicinal Cannabis Research to cultivate cannabis for clinical trials. The measure also protects parents from losing custody of their children as a result of the possession of CBD products. California.

Legislation 59

Legislation Patients Access Banking 59